Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyHealth Net Seladelpar (Livdelzi) Prior Auth | Open…
    Ask Trek AI about this page
    CurrentHealth NetPolicy CP PHAR.698

    Clinical Policy: Seladelpar (Livdelzi)

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.698 alerts

    Get alerted when Policy CP PHAR.698 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governs medical necessity and prior authorization criteria for Seladelpar (Livdelzi) for treatment of primary biliary cholangitis (PBC) for Health Net (Centene-affiliated) lines of business including Commercial, HIM, and Medicaid.

    Policy Summary
    PayerHealth Net
    PolicySeladelpar (Livdelzi) for primary biliary cholangitis
    Policy CodePolicy CP PHAR.698
    Change TypeNo material changes
    Effective DateDec 1, 2024
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing PBC diagnosis, specialist involvement, UDCA trial/failure or contraindication, dose ≤10 mg/day, and supporting labs demonstrating biochemical response.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10 mgmaximum daily dose
    6 moinitial approval duration
    12 mocontinued therapy duration
    ALP ≥1.67×ULNUDCA failure threshold
    state law

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medicaid precedence note

    Coverage and Eligibility Criteria

    inv-01: Initial Therapy

    Covered when ALL of the following are met:

    Initial Approval for PBC: 1) Diagnosis of primary biliary cholangitis (PBC).
    Initial Approval for PBC: 2) Prescribed by or in consultation with a hepatologist or gastroenterologist.
    Initial Approval for PBC: 3) Patient age ≥ 18 years.
    Initial Approval for PBC: 4) Inadequate response to ursodiol (UDCA) defined as sustained elevation in alkaline phosphatase (ALP) ≥ 1.67 × ULN after a ≥ 12‑month trial of UDCA (ursodiol) at a dose ≥ 13 mg/kg/day, unless UDCA is contraindicated or not tolerated.ALP ≥ 1.67 × ULN after ≥12 months of UDCA (≥13 mg/kg/day)

    Follow policy ordering and definitions

    Initial Approval for PBC: 5) Seladelpar prescribed in combination with UDCA unless UDCA is contraindicated or not tolerated.
    Initial Approval for PBC: 6) Requested dose does not exceed 10 mg (1 capsule) per day; approval duration: 6 months.≤ 10 mg/day

    inv-02: Continuation Therapy

    Covered for continuation when ONE of the following is met and patient is responsive:

    Continued Therapy Conditions: a) Member is currently receiving the medication via the Centene benefit or has previously met initial approval criteria; AND member is responding positively to therapy as evidenced by a reduction in ALP from pretreatment level (initial reauthorization).

    If request is for dose increase, new dose must not exceed 10 mg/day; approval duration: 12 months.

    Continued Therapy Conditions: b) Member is currently receiving medication and is enrolled in a state/product with continuity-of-care regulations (see state addendums); AND for subsequent reauthorization, there is continued reduction or maintenance of the initial reduction in ALP level.

    If request is for dose increase, new dose must not exceed 10 mg/day; approval duration: 12 months.

    Requests for use of Seladelpar (Livdelzi) for non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policy (see CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid) or relevant evidence of coverage documents.

    When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid coverage provisions take precedence. Refer to the applicable state Medicaid manual for any state‑specific coverage rules or exceptions that supersede this policy.

    Use of Seladelpar (Livdelzi) is not recommended in patients who have or develop decompensated cirrhosis. Examples of decompensating events include, but are not limited to, ascites, variceal bleeding, and hepatic encephalopathy.

    Key Clinical Thresholds and Coding-related Definitions

    UDCA failure threshold — inv-06
    UDCA failure definitionSustained elevation in alkaline phosphatase (ALP) ≥ 1.67 × ULN after ≥12 months of UDCA (ursodiol) at a dose ≥13 mg/kg/day, or UDCA contraindicated/intolerant
    Minimum UDCA dose in definitionUDCA defined as ursodiol at ≥13 mg/kg/day (AASLD recommendation 13–15 mg/kg/day)
    Minimum UDCA duration in definitionAt least 12 months of continuous UDCA therapy required to assess failure
    Clinical exceptionsUDCA need not be tolerated if there is a contraindication or clinically significant adverse effects

    Prior Authorization, Documentation, and Provider Responsibilities

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Requests must meet initial or continued therapy criteria for Primary Biliary Cholangitis (PBC), including diagnosis of PBC, age ≥ 18 years, prescribed by or in consultation with a hepatologist or gastroenterologist, prescribed in combination with UDCA (ursodiol) unless contraindicated, evidence of prior UDCA failure (sustained ALP ≥ 1.67 × ULN after ≥ 12 months at ≥ 13 mg/kg/day) unless contraindicated, and dose not to exceed 10 mg (1 capsule) per day. Approval duration for initial therapy: 6 months; for continued therapy: 12 months.

    • Initial approval: member ≥ 18 years; diagnosis of Primary Biliary Cholangitis; prescribed by or in consultation with a hepatologist or gastroenterologist; prescribed in combination with UDCA unless contraindicated; documented failure of a ≥ 12-month trial of UDCA (ursodiol) at ≥ 13 mg/kg/day with sustained ALP ≥ 1.67 × ULN unless contraindicated; max dose 10 mg/day. Approval duration: 6 months.
    • Continued therapy: member currently receiving medication via Centene benefit or previously met initial criteria; member responding positively (initial reauthorization: reduction in ALP from pretreatment; subsequent reauthorization: continued reduction or maintenance); dose increases must not exceed 10 mg/day. Approval duration: 12 months.
    Note

    Therapeutic Background and Agent Summary

    Seladelpar (brand name Livdelzi) is a peroxisome proliferator‑activated receptor‑delta (PPAR‑delta) agonist approved under accelerated approval for the treatment of primary biliary cholangitis (PBC) in adults with an inadequate response to ursodeoxycholic acid (UDCA), or as monotherapy for patients unable to tolerate UDCA. Approval was based on reductions in alkaline phosphatase (ALP); improvement in survival or prevention of liver decompensation has not been demonstrated.

    Definitions and Trial Response Criteria

    Biochemical response (trial definition) — inv-16
    Biochemical response (trial definition)ALP < 1.67 × ULN; ALP decrease ≥15% from baseline; and total bilirubin ≤ ULN (ULN ALP = 116 U/L; ULN TB = 1.1 mg/dL)
    ALP upper limit referenceULN for ALP defined as 116 U/L in the Livdelzi trial
    Total bilirubin upper limitULN for total bilirubin defined as 1.1 mg/dL in the Livdelzi trial
    PBC diagnosis criteria — inv-17
    Diagnostic rule for PBCDiagnosis established when two of the following are met: elevated ALP; positive anti-mitochondrial antibody (AMA) or other PBC-specific autoantibodies; histologic evidence on liver biopsy
    ALP criterionALP elevated above the laboratory upper limit of normal (per local reference)
    Policy Summary
    PayerHealth Net
    PolicySeladelpar (Livdelzi) for primary biliary cholangitis
    Policy CodePolicy CP PHAR.698
    Change TypeNo material changes
    Effective DateDec 1, 2024
    Next Review Date
    Key ActionSubmit prior authorization with documentation showing PBC diagnosis, specialist involvement, UDCA trial/failure or contraindication, dose ≤10 mg/day, and supporting labs demonstrating biochemical response.
    SourceLink
    On This Page
    Coverage and Eligibility CriteriaKey Clinical Thresholds and Coding-related DefinitionsPrior Authorization, Documentation, and Provider ResponsibilitiesTherapeutic Background and Agent SummaryDefinitions and Trial Response Criteria

    Prior Authorization (operational)

    The document does not list specific billing or PA code numbers in this section; providers should follow payer prior authorization submission processes and include all supporting clinical information per the plan's PA operational requirements.

    Denial Risk

    Denial Risk for Non‑Covered Indications

    Requests for indications that are not FDA‑approved and not addressed in this policy may be denied unless sufficient documentation of efficacy and safety is provided per applicable off‑label use policies (commercial: CP.CPA.09; marketplace: HIM.PA.154; Medicaid: CP.PMN.53) or other evidence of coverage documents.

    Step Therapy

    Therapeutic Alternatives / Step Therapy

    Therapeutic alternative: ursodiol (ursodeoxycholic acid, UDCA) is the preferred/required alternative and should be used at recommended dosing (example: up to 15 mg/kg/day per Appendix B), unless contraindicated or not tolerated. Documentation of a sufficient trial and failure of UDCA (see PA criteria) is required when applicable.

    • Preferred alternative: ursodiol (UDCA).
    • UDCA dosing guidance referenced in Appendix B (example dosing up to 15 mg/kg/day).
    • A ≥ 12‑month trial of UDCA at ≥ 13 mg/kg/day with documentation of sustained ALP elevation (≥ 1.67 × ULN) is required to demonstrate treatment failure unless contraindicated.
    Documentation Required

    Documentation and Contractual Notice

    Provider must submit documentation (office chart notes, lab results, and other clinical information) supporting that the member has met all applicable criteria. Providers, members, and their representatives are bound by the payer's contractual terms; unauthorized copying or distribution of this policy is prohibited.

    Serology criterionPositive AMA or other PBC-specific autoantibodies (e.g., sp100, gp210) if AMA is negative
    Histology criterionLiver biopsy demonstrating histologic evidence consistent with PBC